Alison H. Goodall

Professor Alison H. Goodall is a Professor of Thrombosis and Haemostasis at the University of Leicester's Department of Cardiovascular Sciences. She holds a PhD in Biochemistry from London University and has been a leading figure in vascular biology research since 1997. Her work focuses on thrombosis regulation, atherosclerosis, and cross-talk between vascular cells. She co-founded Haemostatix Ltd, a University spin-out company developing anticoagulant therapies, sold in 2016 after successful clinical trials.

Her research explores platelet-monocyte interactions in cardiovascular disease, cancer, and dementia. Key areas include procoagulant platelet signaling, microparticle biology, and genetic factors like TRIB1/3 in atherogenesis. Her studies bridge clinical and basic science, with contributions to diagnostic markers (e.g., exhaled breath metabolites) and anticoagulant drug mechanisms (e.g., heparin-aspirin interactions).

Publications highlight platelet activation in acute kidney injury post-cardiac surgery, mathematical coagulation modeling, and molecular pathways in aging macrophages. She has also investigated thrombotic risks in cancer patients and lipid mediator profiles from platelet activation. Despite her extensive contributions, no specific scientific awards are listed.

Her work integrates translational research across academia and industry, with ongoing studies on tumor-associated macrophages, miRNA-driven pathways, and proteomic stratification of myocardial infarction. Collaborations span cardiology, oncology, and immunology, reflecting her interdisciplinary approach to vascular disease mechanisms.